A Recovery-Oriented Program for People with Bipolar Disorder through Virtual Reality-Based Cognitive Remediation: Results of a Feasibility Randomized Clinical Trial

• Published in: Journal of clinical medicine 2023-03, Vol.12 (6), p.2142
• Main Authors: Perra, Alessandra, Galetti, Alessia, Zaccheddu, Rosanna, Locci, Aurora, Piludu, Federica, Preti, Antonio, Primavera, Diego, Di Natale, Lorenzo, Nardi, Antonio Egidio, Kurotshka, Peter Konstantin, Cossu, Giulia, Sancassiani, Federica, Stella, Giusy, De Lorenzo, Valerio, Zreik, Thurayya, Carta, Mauro Giovanni
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Bipolar disorder; Care and treatment; Clinical medicine; Cognition & reasoning; Cognition disorders; Cognitive ability; Cognitive therapy; Dementia; Feasibility studies; Intervention; Memory; Mental disorders; Mental health care; Physical fitness; Rehabilitation; Schizophrenia; Testing; Virtual reality
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12062142

Cognitive impairment is a frequent consequence of bipolar disorder (BD) that is difficult to prevent and treat. In addition, the quality of the preliminary evidence on the treatment of BD through Cognitive Remediation (CR) with traditional methods is poor. This study aims to evaluate the feasibility of a CR intervention with fully immersive Virtual Reality (VR) as an additional treatment for BD and offers preliminary data on its efficacy. Feasibility randomized controlled cross-over clinical study, with experimental condition lasting three months, crossed between two groups. Experimental condition: CR fully immersive VR recovery-oriented program plus conventional care; Control condition: conventional care. The control group began the experimental condition after a three months period of conventional care (waiting list). After the randomization of 50 people with BD diagnosis, the final sample consists of 39 participants in the experimental condition and 25 in the control condition because of dropouts. Acceptability and tolerability of the intervention were good. Compared to the waitlist group, the experimental group reported a significant improvement regarding cognitive functions (memory: = 0.003; attention: = 0.002, verbal fluency: = 0.010, executive function: = 0.003), depressive symptoms ( = 0.030), emotional awareness ( = 0.007) and biological rhythms ( = 0.029). The results are preliminary and cannot be considered exhaustive due to the small sample size. However, the evidence of efficacy, together with the good acceptability of the intervention, is of interest. These results suggest the need to conduct studies with larger samples that can confirm this data. ClinicalTrialsgov NCT05070065, registered in September 2021.